Compare JRSH & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JRSH | VERU |
|---|---|---|
| Founded | 2016 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 41.7M |
| IPO Year | 2018 | 1990 |
| Metric | JRSH | VERU |
|---|---|---|
| Price | $3.23 | $2.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.00 | ★ $22.50 |
| AVG Volume (30 Days) | ★ 121.5K | 120.5K |
| Earning Date | 02-09-2026 | 02-11-2026 |
| Dividend Yield | ★ 5.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $152,618,454.00 | N/A |
| Revenue This Year | $11.71 | N/A |
| Revenue Next Year | $7.69 | N/A |
| P/E Ratio | $23.82 | ★ N/A |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $2.81 | $2.10 |
| 52 Week High | $4.17 | $7.40 |
| Indicator | JRSH | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 40.52 |
| Support Level | $3.06 | $2.20 |
| Resistance Level | $3.60 | $2.50 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 31.58 | 7.83 |
Jerash Holdings (US) Inc along with its subsidiaries, is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers, including Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen, which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, and Speedo. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.